


Amendments to the Claims

1. (Currently Amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R₁ is the group ($\text{C}_5\text{-}\text{C}_7$)alkyl, ($\text{C}_4\text{-}\text{C}_{12}$)haloalkyl, -CF₃, allyl, ($\text{C}_4\text{-}\text{C}_{12}$)alkenyl, ($\text{C}_4\text{-}\text{C}_{12}$)alkynyl, ($\text{C}_1\text{-}\text{C}_8$)alkylcycloalkyl, ($\text{C}_3\text{-}\text{C}_8$)cycloalkyl, substituted benzyl, ($\text{C}_1\text{-}\text{C}_{12}$)alkylheterocyclic radical, ($\text{C}_2\text{-}\text{C}_4$), and ($\text{C}_2\text{-}\text{C}_4$)alkylaryl, or aryl wherein the aryl or heterocyclic group is optionally substituted and the benzyl is substituted with 1 to 2 or 3 groups independently selected from ($\text{C}_1\text{-}\text{C}_{12}$)alkyl, ($\text{C}_2\text{-}\text{C}_{12}$)alkenyl, ($\text{C}_1\text{-}\text{C}_{12}$)alkoxy, ($\text{C}_4\text{-}\text{C}_8$)alkylcycloalkyl, and ($\text{C}_1\text{-}\text{C}_{12}$)haloalkyl;

R₂ is hydrogen;

R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, ($\text{C}_1\text{-}\text{C}_4$)alkyl, ($\text{C}_2\text{-}\text{C}_4$)alkenyl, -O-($\text{C}_1\text{-}\text{C}_3$ alkyl), COOH, C(O)($\text{C}_1\text{-}\text{C}_3$ alkyl), C(O)O($\text{C}_1\text{-}\text{C}_3$ alkyl), -CF₃, and halo ($\text{C}_2\text{-}\text{C}_{12}$)alkyl, ($\text{C}_4\text{-}\text{C}_{12}$)haloalkyl, ($\text{C}_4\text{-}\text{C}_{12}$)alkoxyalkyl, ($\text{C}_4\text{-}\text{C}_{10}$)thioalkyl, hydroxy, ($\text{C}_2\text{-}\text{C}_{12}$)alkenyl, ($\text{C}_2\text{-}\text{C}_{12}$)alkynyl, ($\text{C}_4\text{-}\text{C}_{12}$)alkylaryl, ($\text{C}_4\text{-}\text{C}_{12}$)alkylecycloalkyl, ($\text{C}_4\text{-}\text{C}_{12}$)alkylheterocyclic, C(O)C₄-C₆alkyl, C(O)OC₄-C₆alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substituents selected from halo, amino, halo-C₄-C₆alkyl, ($\text{C}_2\text{-}\text{C}_6$)alkenyl, ($\text{C}_4\text{-}\text{C}_6$)haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. (Canceled)


3. (Currently Amended) A compound according to Claim 1 wherein R₁, is allyl(C₅-C₇)alkyl, (C₄-C₆)alkenyl, -O-(C₁-C₃-alkyl), (C₃-C₄)alkylcycloalkyl, or -CF₃, or aryl.

4. (Currently Amended) A compound according to Claim 1 wherein R₁, is benzyl substituted with 2 substitutents selected from (C₁-C₆)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃-alkyl), (C₁-C₄)alkylecycloalkyl, and -CF₃.

5. (Canceled)

6. (Currently Amended) The compound of Claim 1 wherein R₅ is the group represented by COOH, C(O)(C₁-C₃-alkyl), C(O)O(C₁-C₃-alkyl), chloro, bromo or CF₃.


7. (Currently Amended) A compound of formula (I)




wherein R₁ through R₆ are selected to provide a compound selected from the group consisting of:
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid allylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid pentylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid hexylamide;
3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (5-methyl hexyl) amide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;
~~3-Oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid (2 thiophen 2 yl ethyl) amide;~~
~~3-Oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid (3 phenyl propyl) amide;~~
~~3-Oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid (4 phenyl butyl) amide;~~
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
~~5 Methyl 3 oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid butylamide;~~
~~6 Chloro 3 oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid propylamide;~~
~~6 Chloro 3 oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid isopropylamide;~~
~~6 Chloro 3 oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid butylamide;~~
~~6 Chloro 3 oxo 3*H* benzo[*d*]isothiazole 2 carboxylic acid hexylamide;~~
6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide; and


8. (Currently Amended) A benzisothiazole-3(2*H*)-one compound represented by the formulae below (C1), (C2), (C3), or (C4):




(C1),



(C2),




(C3),



9. (Currently Amended) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10. (Currently Amended) A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1




I

or a pharmaceutical acceptable salt, solvate, or prodrug thereof.

11. (Canceled).

12. (Currently Amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein R₁-R₆ are defined as in claim 1




formulated for the treatment and/or amelioration of the effect of elevated hepatic lipase and/or endothelial lipase activity.

13-15. (Canceled)

16. (Previously Presented) The method of claim 10 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.

17. (Canceled)

18. (New) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.